Lung Cancer:@0.792682:0.035749:0.914564:0.035749:0.914564:0.019993:0.792682:0.019993:0.008890:0.011699:0.011738:0.012950:0.005330:0.015644:0.013143:0.011738:0.012450:0.012508:0.005792
TREATMENT APPROACHES:@0.983689:0.278245:0.983689:0.065272:0.955679:0.065272:0.955679:0.278245:0.000000:0.000000:0.000000:0.057096:-0.123230:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.375913
35:@0.955522:0.038184:0.976595:0.038184:0.976595:0.018587:0.955522:0.018587:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.679047:0.970015:0.915156:0.970015:0.915156:0.956010:0.679047:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
frequently used in the palliative setting in :@0.084242:0.096166:0.480488:0.096166:0.480488:0.080410:0.084242:0.080410:0.006042:0.005711:0.012508:0.013123:0.011699:0.012508:0.011738:0.006523:0.003848:0.010314:0.007339:0.011699:0.007466:0.012508:0.013181:0.007341:0.003848:0.011738:0.007341:0.006523:0.011738:0.012508:0.007331:0.013123:0.013143:0.003848:0.003848:0.003848:0.013143:0.006523:0.003868:0.010660:0.012508:0.007351:0.007466:0.012508:0.006523:0.006523:0.003848:0.011738:0.012950:0.007333:0.003848:0.011738:0.005330
patients with lung cancer because of its :@0.084242:0.112490:0.480463:0.112490:0.480463:0.096734:0.084242:0.096734:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.008370:0.015990:0.003848:0.006523:0.011738:0.008370:0.003848:0.011699:0.011738:0.012950:0.008370:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.008370:0.013123:0.012508:0.012450:0.013143:0.011699:0.007466:0.012508:0.008370:0.012604:0.006042:0.008370:0.003848:0.006523:0.007466:0.005330
tolerability. Data are available for the use :@0.084242:0.128815:0.480490:0.128815:0.480490:0.113059:0.084242:0.113059:0.006523:0.012604:0.003848:0.012508:0.005792:0.013143:0.013123:0.003848:0.003848:0.003848:0.006523:0.010314:0.005330:0.006177:0.014316:0.013143:0.006523:0.013143:0.006177:0.013143:0.005715:0.012508:0.006167:0.013143:0.010660:0.013143:0.003848:0.003848:0.013143:0.013123:0.003848:0.012529:0.006167:0.006042:0.012604:0.005792:0.006159:0.006523:0.011738:0.012508:0.006161:0.011699:0.007466:0.012508:0.005330
of cisplatin in the adjuvant setting.:@0.084242:0.145140:0.402762:0.145140:0.402762:0.129384:0.084242:0.129384:0.012604:0.006042:0.005330:0.012450:0.003848:0.007466:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.005330:0.003848:0.011738:0.005330:0.006523:0.011738:0.012508:0.005330:0.013143:0.013181:0.003906:0.011699:0.010660:0.013143:0.011738:0.006523:0.005330:0.007466:0.012508:0.006523:0.006523:0.003848:0.011738:0.012950:0.005330
STAGE IIIA AND IIIB:@0.084242:0.178129:0.277949:0.178129:0.277949:0.160314:0.084242:0.160314:0.011118:0.008980:0.015822:0.017960:0.011118:0.005987:0.005987:0.005987:0.005987:0.015822:0.005987:0.015822:0.015822:0.014966:0.005987:0.005987:0.005987:0.005987:0.012401
Stage III consists of patients with locally ad-:@0.084242:0.195604:0.475152:0.195604:0.475152:0.179848:0.084242:0.179848:0.009583:0.006523:0.013143:0.012950:0.012508:0.004166:0.004349:0.004349:0.004349:0.004176:0.012450:0.012604:0.011738:0.007466:0.003848:0.007466:0.006523:0.007466:0.004176:0.012604:0.006042:0.004166:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.004176:0.015990:0.003848:0.006523:0.011738:0.004176:0.003848:0.012604:0.012450:0.013143:0.003848:0.003848:0.010314:0.004176:0.013143:0.013181:0.006388
vanced disease. Tumours are of all dimen-:@0.084242:0.211928:0.475140:0.211928:0.475140:0.196173:0.084242:0.196173:0.010660:0.013143:0.011738:0.012450:0.012508:0.013181:0.005099:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.005099:0.007310:0.011699:0.018049:0.012604:0.011699:0.005792:0.007466:0.005090:0.013143:0.005715:0.012508:0.005099:0.012604:0.006042:0.005099:0.013143:0.003848:0.003848:0.005099:0.013181:0.003848:0.018049:0.012508:0.011738:0.006388
sions with spread to  mediastinal nodes. :@0.084242:0.228253:0.480492:0.228253:0.480492:0.212497:0.084242:0.212497:0.007466:0.003848:0.012604:0.011738:0.007466:0.011064:0.015990:0.003848:0.006523:0.011738:0.011064:0.007466:0.013123:0.005719:0.012508:0.013143:0.013181:0.011064:0.006523:0.012604:0.005330:0.005721:0.018049:0.012508:0.013181:0.003848:0.013143:0.007466:0.006523:0.003848:0.011738:0.013143:0.003848:0.011064:0.011738:0.012604:0.013181:0.012508:0.007466:0.005330:0.005330
Tumours are greater than 5  cm with any :@0.084242:0.244578:0.480476:0.244578:0.480476:0.228822:0.084242:0.228822:0.007310:0.011699:0.018049:0.012604:0.011699:0.005792:0.007466:0.008313:0.013143:0.005715:0.012508:0.008313:0.012950:0.005711:0.012508:0.013143:0.006523:0.012508:0.005792:0.008313:0.006523:0.011738:0.013143:0.011738:0.008313:0.010660:0.005330:0.002983:0.012450:0.018049:0.008313:0.015990:0.003848:0.006523:0.011738:0.008313:0.013143:0.011738:0.010314:0.005330
nodal involvement or more than 7 cm with :@0.084242:0.260903:0.480494:0.260903:0.480494:0.245147:0.084242:0.245147:0.011738:0.012604:0.013181:0.013143:0.003848:0.004580:0.003848:0.011738:0.010660:0.012604:0.003848:0.010660:0.012508:0.018049:0.012508:0.011738:0.006523:0.004580:0.012604:0.005792:0.004580:0.018049:0.012604:0.005707:0.012508:0.004580:0.006523:0.011738:0.013143:0.011738:0.004580:0.010660:0.004580:0.012450:0.018049:0.004580:0.015990:0.003848:0.006523:0.011738:0.005330
or without nodal involvement.:@0.084242:0.277228:0.362083:0.277228:0.362083:0.261472:0.084242:0.261472:0.012604:0.005792:0.005330:0.015990:0.003848:0.006523:0.011738:0.012604:0.011699:0.006523:0.005330:0.011738:0.012604:0.013181:0.013143:0.003848:0.005330:0.003848:0.011738:0.010660:0.012604:0.003848:0.010660:0.012508:0.018049:0.012508:0.011738:0.006523:0.005330
The  cornerstone  of treatment for  these :@0.084242:0.293552:0.480505:0.293552:0.480505:0.277796:0.084242:0.277796:0.008197:0.011738:0.012508:0.005330:0.006531:0.012450:0.012604:0.006188:0.011738:0.012508:0.005792:0.007466:0.006523:0.012604:0.011738:0.012508:0.005330:0.006523:0.012604:0.006042:0.011873:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.011873:0.006042:0.012604:0.005792:0.005330:0.006533:0.006523:0.011738:0.012508:0.007466:0.012508:0.005330
patients is combined radiotherapy  and :@0.084242:0.309877:0.480507:0.309877:0.480507:0.294121:0.084242:0.294121:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.011873:0.003848:0.007466:0.011873:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.012508:0.013181:0.011873:0.005792:0.013143:0.013181:0.003848:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.006529:0.013143:0.011738:0.013181:0.005330
chemotherapy. Randomised studies show :@0.084242:0.326202:0.480469:0.326202:0.480469:0.310446:0.084242:0.310446:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005721:0.011680:0.013143:0.011738:0.013181:0.012604:0.018049:0.003848:0.007466:0.012508:0.013181:0.005734:0.007466:0.006523:0.011699:0.013181:0.003848:0.012508:0.007466:0.005734:0.007466:0.011738:0.012604:0.015990:0.005330
an improvement in survival  with concur-:@0.084242:0.342527:0.475152:0.342527:0.475152:0.326771:0.084242:0.326771:0.013143:0.011738:0.009352:0.003848:0.018049:0.013123:0.005713:0.012604:0.010660:0.012508:0.018049:0.012508:0.011738:0.006523:0.009352:0.003848:0.011738:0.009352:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330:0.004041:0.015990:0.003848:0.006523:0.011738:0.009352:0.012450:0.012604:0.011738:0.012450:0.011699:0.005794:0.006388
rent  chemotherapy plus radiation  thera-:@0.084242:0.358852:0.475152:0.358852:0.475152:0.343096:0.084242:0.343096:0.005713:0.012508:0.011738:0.006523:0.005330:0.004141:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012494:0.005792:0.013143:0.013123:0.010314:0.009487:0.013123:0.003848:0.011699:0.007466:0.009487:0.005792:0.013143:0.013181:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.004145:0.006523:0.011738:0.012508:0.005792:0.013127:0.006388
py:@0.084242:0.375176:0.107680:0.375176:0.107680:0.359420:0.084242:0.359420:0.013123:0.010314
 versus :@0.107680:0.375176:0.178165:0.375176:0.178165:0.359420:0.107680:0.359420:0.009563:0.010660:0.012508:0.005792:0.007466:0.011699:0.007466:0.005330
radiation therapy alone or  ra-:@0.182398:0.375176:0.475152:0.375176:0.475152:0.359420:0.182398:0.359420:0.005792:0.013143:0.013181:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.009563:0.006523:0.011738:0.012508:0.005792:0.013133:0.013123:0.010314:0.009563:0.013143:0.003848:0.012604:0.011738:0.012508:0.009563:0.012604:0.005792:0.005330:0.004224:0.005792:0.013143:0.006388
diotherapy followed by chemotherapy. :@0.084242:0.391501:0.480501:0.391501:0.480501:0.375745:0.084242:0.375745:0.013181:0.003848:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.012758:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.012508:0.013181:0.012758:0.013123:0.010314:0.012758:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005330
There  is,  however,  an  increase  in  severe :@0.084242:0.407826:0.480486:0.407826:0.480486:0.392070:0.084242:0.392070:0.008197:0.011738:0.012508:0.005703:0.012508:0.005330:0.004220:0.003848:0.007466:0.005330:0.005330:0.004218:0.011738:0.012604:0.015990:0.012508:0.010660:0.012508:0.003770:0.005330:0.005330:0.004218:0.013143:0.011738:0.005330:0.004222:0.003848:0.011738:0.012450:0.005713:0.012508:0.013143:0.007466:0.012508:0.005330:0.004222:0.003848:0.011738:0.005330:0.004222:0.007466:0.012508:0.010660:0.012508:0.005717:0.012508:0.005330
oesophagitis in patients receiving concur-:@0.084242:0.424151:0.475152:0.424151:0.475152:0.408395:0.084242:0.408395:0.012604:0.012508:0.007466:0.012604:0.013123:0.011738:0.013143:0.012950:0.003848:0.006523:0.003848:0.007466:0.005830:0.003848:0.011738:0.005830:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005830:0.005713:0.012508:0.012450:0.012508:0.003848:0.010660:0.003848:0.011738:0.012950:0.005821:0.012450:0.012604:0.011738:0.012450:0.011699:0.005765:0.006388
rent treatment. Patients with good PS (0-2) :@0.084242:0.440476:0.480469:0.440476:0.480469:0.424720:0.084242:0.424720:0.005713:0.012508:0.011738:0.006523:0.005065:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.005061:0.011392:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005068:0.015990:0.003848:0.006523:0.011738:0.005070:0.012950:0.012604:0.012604:0.013181:0.005065:0.011392:0.009583:0.005068:0.007100:0.010660:0.006388:0.010660:0.007100:0.005330
are best so treated.:@0.084242:0.456800:0.266703:0.456800:0.266703:0.441044:0.084242:0.441044:0.013143:0.005715:0.012508:0.005330:0.013123:0.012508:0.007466:0.006523:0.005330:0.007466:0.012604:0.005330:0.006523:0.005700:0.012508:0.013143:0.006523:0.012508:0.013181:0.005330
11:@0.266698:0.451233:0.279128:0.451233:0.279128:0.442047:0.266698:0.442047:0.006215:0.006215
Surgery has not been found to be ben-:@0.102424:0.473180:0.475159:0.473180:0.475159:0.457424:0.102424:0.457424:0.009583:0.011699:0.005805:0.012950:0.012508:0.005792:0.010314:0.006743:0.011738:0.013143:0.007466:0.006754:0.011738:0.012604:0.006523:0.006739:0.013123:0.012508:0.012508:0.011738:0.006744:0.006042:0.012604:0.011699:0.011738:0.013181:0.006741:0.006523:0.012604:0.006743:0.013123:0.012508:0.006754:0.013123:0.012508:0.011738:0.006388
eficial in patients with non-bulky disease. :@0.084240:0.489505:0.480472:0.489505:0.480472:0.473749:0.084240:0.473749:0.012508:0.004686:0.004686:0.012450:0.003848:0.013143:0.003848:0.008126:0.003848:0.011738:0.008122:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.008124:0.015990:0.003848:0.006523:0.011738:0.008120:0.011738:0.012604:0.011738:0.006388:0.013123:0.011699:0.003848:0.009660:0.010314:0.008120:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.005330
Patients  have been  randomised to  re-:@0.084240:0.505829:0.475167:0.505829:0.475167:0.490073:0.084240:0.490073:0.011392:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.007589:0.011738:0.013143:0.010660:0.012508:0.012931:0.013123:0.012508:0.012508:0.011738:0.005330:0.007589:0.005792:0.013143:0.011738:0.013181:0.012604:0.018049:0.003848:0.007466:0.012508:0.013181:0.012931:0.006523:0.012604:0.005330:0.007585:0.005713:0.012508:0.006388
ceive either  concurrent  chemoradiation :@0.084240:0.522154:0.480493:0.522154:0.480493:0.506398:0.084240:0.506398:0.012450:0.012508:0.003848:0.010660:0.012508:0.010564:0.012508:0.003848:0.006523:0.011738:0.012508:0.005792:0.005330:0.005219:0.012450:0.012604:0.011738:0.012450:0.011699:0.005792:0.005700:0.012508:0.011738:0.006523:0.005330:0.005220:0.012450:0.011738:0.012508:0.018049:0.012604:0.005792:0.013143:0.013181:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330
followed by either  surgical resection or :@0.084240:0.538479:0.480482:0.538479:0.480482:0.522723:0.084240:0.522723:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.012508:0.013181:0.011796:0.013123:0.010314:0.011796:0.012508:0.003848:0.006523:0.011738:0.012508:0.005792:0.005330:0.006456:0.007466:0.011699:0.005807:0.012950:0.003848:0.012450:0.013143:0.003848:0.011796:0.005711:0.012508:0.007466:0.012508:0.012450:0.006523:0.003848:0.012604:0.011738:0.011796:0.012604:0.005792:0.005330
continuation of radiation therapy, but no :@0.084240:0.554804:0.480507:0.554804:0.480507:0.539048:0.084240:0.539048:0.012450:0.012604:0.011738:0.006523:0.003848:0.011738:0.011699:0.013143:0.006523:0.003848:0.012604:0.011738:0.007158:0.012604:0.006042:0.007177:0.005792:0.013143:0.013181:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.007177:0.006523:0.011738:0.012508:0.005780:0.013143:0.013123:0.010314:0.005330:0.007177:0.013123:0.011699:0.006523:0.007177:0.011738:0.012604:0.005330
significant  difference  in  overall  survival :@0.084240:0.571129:0.480468:0.571129:0.480468:0.555373:0.084240:0.555373:0.007466:0.003848:0.012950:0.011738:0.003848:0.004686:0.004686:0.012450:0.013143:0.011738:0.006523:0.005330:0.008698:0.013181:0.003848:0.006104:0.006042:0.012508:0.005711:0.012508:0.011738:0.012450:0.012508:0.005330:0.008694:0.003848:0.011738:0.005330:0.008701:0.012604:0.010660:0.012508:0.005792:0.013143:0.003848:0.003848:0.005330:0.008705:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330
was found.  However,  there  were greater :@0.084240:0.587453:0.480495:0.587453:0.480495:0.571697:0.084240:0.571697:0.015990:0.013143:0.007466:0.008486:0.006042:0.012604:0.011699:0.011738:0.013181:0.005330:0.005330:0.003137:0.013143:0.012604:0.015990:0.012508:0.010660:0.012508:0.003768:0.005330:0.005330:0.003146:0.006523:0.011738:0.012508:0.005705:0.012508:0.005330:0.003146:0.015990:0.012508:0.005711:0.012508:0.008486:0.012950:0.005709:0.012508:0.013143:0.006523:0.012508:0.005792:0.005330
treatment-related mortalities in the sur-:@0.084240:0.603778:0.475151:0.603778:0.475151:0.588022:0.084240:0.588022:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.006388:0.005703:0.012508:0.003848:0.013143:0.006523:0.012508:0.013181:0.013008:0.018049:0.012604:0.005792:0.006523:0.013143:0.003848:0.003848:0.006523:0.003848:0.012508:0.007466:0.013008:0.003848:0.011738:0.013008:0.006523:0.011738:0.012508:0.013008:0.007466:0.011699:0.005792:0.006388
gery arm compared to the chemoradia-:@0.084240:0.620103:0.475167:0.620103:0.475167:0.604347:0.084240:0.604347:0.012950:0.012508:0.005792:0.010314:0.007662:0.013143:0.006325:0.018049:0.007678:0.012450:0.012604:0.018049:0.013123:0.013143:0.005717:0.012508:0.013181:0.007668:0.006523:0.012604:0.007662:0.006523:0.011738:0.012508:0.007662:0.012450:0.011738:0.012508:0.018049:0.012604:0.005792:0.013143:0.013181:0.003848:0.013143:0.006388
tion-alone arm (8%:@0.084240:0.636428:0.260830:0.636428:0.260830:0.620672:0.084240:0.620672:0.006523:0.003848:0.012604:0.011738:0.006388:0.013143:0.003848:0.012604:0.011738:0.012508:0.005721:0.013143:0.006327:0.018049:0.005734:0.007100:0.010660:0.014913
 versus:@0.260830:0.636428:0.322155:0.636428:0.322155:0.620672:0.260830:0.620672:0.005734:0.010660:0.012508:0.005792:0.007466:0.011699:0.007466
 2%), particularly :@0.322155:0.636428:0.480482:0.636428:0.480482:0.620672:0.322155:0.620672:0.005734:0.010660:0.014913:0.007100:0.005330:0.005734:0.013123:0.013143:0.005792:0.006523:0.003848:0.012450:0.011699:0.003848:0.013143:0.005792:0.003848:0.010314:0.005330
for patients undergoing a pneumonec-:@0.084240:0.652752:0.475150:0.652752:0.475150:0.636997:0.084240:0.636997:0.006042:0.012604:0.005792:0.011661:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.011661:0.011699:0.011738:0.013181:0.012508:0.005807:0.012950:0.012604:0.003848:0.011738:0.012950:0.011661:0.013143:0.011661:0.013123:0.011738:0.012508:0.011699:0.018049:0.012604:0.011738:0.012508:0.012434:0.006388
tomy.:@0.084240:0.669077:0.137060:0.669077:0.137060:0.653321:0.084240:0.653321:0.006523:0.012604:0.018049:0.010314:0.005330
12:@0.137056:0.663497:0.149485:0.663497:0.149485:0.654311:0.137056:0.654311:0.006215:0.006215
STAGE IV:@0.084242:0.702095:0.176178:0.702095:0.176178:0.684280:0.084242:0.684280:0.011118:0.008980:0.015822:0.017960:0.011118:0.005987:0.005987:0.014966
The  tumour  has spread to  the contralat-:@0.084242:0.719570:0.475152:0.719570:0.475152:0.703814:0.084242:0.703814:0.008197:0.011738:0.012508:0.005330:0.003429:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.005330:0.003427:0.011738:0.013143:0.007466:0.008775:0.007466:0.013123:0.005719:0.012508:0.013143:0.013181:0.008775:0.006523:0.012604:0.005330:0.003431:0.006523:0.011738:0.012508:0.008775:0.012450:0.012604:0.011738:0.006523:0.005792:0.013143:0.003848:0.013143:0.006489:0.006388
eral lung, or the patient has a malignant :@0.084242:0.735895:0.480515:0.735895:0.480515:0.720139:0.084242:0.720139:0.012508:0.005792:0.013143:0.003848:0.007582:0.003848:0.011699:0.011738:0.012950:0.005330:0.007570:0.012604:0.005792:0.007568:0.006523:0.011738:0.012508:0.007582:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007582:0.011738:0.013143:0.007466:0.007582:0.013143:0.007582:0.018049:0.013143:0.003848:0.003848:0.012950:0.011738:0.013143:0.011738:0.006523:0.005330
pleural or  pericardial effusion.  This stage :@0.084242:0.752219:0.480490:0.752219:0.480490:0.736464:0.084242:0.736464:0.013123:0.003848:0.012508:0.011699:0.005792:0.013143:0.003848:0.009371:0.012604:0.005792:0.005330:0.004026:0.013123:0.012508:0.005792:0.003848:0.012450:0.013143:0.005677:0.013181:0.003848:0.013143:0.003848:0.009371:0.012508:0.006096:0.006042:0.011699:0.007466:0.003848:0.012604:0.011738:0.005330:0.005330:0.004029:0.008197:0.011738:0.003848:0.007466:0.009371:0.007466:0.006523:0.013143:0.012950:0.012508:0.005330
includes tumours which have spread out-:@0.084242:0.768544:0.475152:0.768544:0.475152:0.752788:0.084242:0.752788:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.007466:0.006843:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.007466:0.006831:0.015990:0.011738:0.003848:0.012450:0.011738:0.006831:0.011738:0.013143:0.010660:0.012508:0.006831:0.007466:0.013123:0.005719:0.012508:0.013143:0.013181:0.006831:0.012604:0.011699:0.006527:0.006388
side of the thorax.:@0.084242:0.784869:0.251016:0.784869:0.251016:0.769113:0.084242:0.769113:0.007466:0.003848:0.013181:0.012508:0.005330:0.012604:0.006042:0.005330:0.006523:0.011738:0.012508:0.005330:0.006523:0.011738:0.012604:0.005792:0.013143:0.009236:0.005330
TREATMENT:@0.084242:0.818185:0.207950:0.818185:0.207950:0.798588:0.084242:0.798588:0.009878:0.013641:0.012230:0.017404:0.009878:0.021167:0.012230:0.017404:0.009878
FIRST-LINE CHEMOTHERAPY:@0.084242:0.837129:0.357912:0.837129:0.357912:0.819314:0.084242:0.819314:0.010263:0.005987:0.012401:0.011118:0.008980:0.008980:0.009407:0.005987:0.015822:0.011118:0.005987:0.016677:0.014539:0.011118:0.019242:0.017960:0.008980:0.014539:0.011118:0.012401:0.015822:0.011973:0.013256
Chemotherapy  results in an increase in :@0.084242:0.854604:0.480467:0.854604:0.480467:0.838848:0.084242:0.838848:0.015644:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005973:0.005713:0.012508:0.007466:0.011699:0.003848:0.006523:0.007466:0.011315:0.003848:0.011738:0.011315:0.013143:0.011738:0.011315:0.003848:0.011738:0.012450:0.005713:0.012508:0.013143:0.007466:0.012508:0.011315:0.003848:0.011738:0.005330
survival and quality of life (QoL) in select-:@0.084242:0.870928:0.475160:0.870928:0.475160:0.855173:0.084242:0.855173:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.006947:0.013143:0.011738:0.013181:0.006947:0.013123:0.011699:0.013143:0.003848:0.003848:0.006523:0.010314:0.006947:0.012604:0.006042:0.006935:0.003848:0.003848:0.006042:0.012508:0.006947:0.007100:0.016760:0.012604:0.008890:0.007100:0.006947:0.003848:0.011738:0.006947:0.007466:0.012508:0.003848:0.012508:0.012450:0.006523:0.006388
ed patients with metastatic NSCLC.  The :@0.084242:0.887253:0.480492:0.887253:0.480492:0.871497:0.084242:0.871497:0.012508:0.013181:0.010064:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.010064:0.015990:0.003848:0.006523:0.011738:0.010064:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.010064:0.014239:0.009583:0.015644:0.008890:0.015644:0.005330:0.005330:0.004724:0.008197:0.011738:0.012508:0.005330
one-year-survival rate increases from 10% :@0.084242:0.903578:0.480459:0.903578:0.480459:0.887822:0.084242:0.887822:0.012604:0.011738:0.012508:0.006388:0.010314:0.012508:0.013143:0.005792:0.006388:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.007235:0.005792:0.013143:0.006523:0.012508:0.007235:0.003848:0.011738:0.012450:0.005713:0.012508:0.013143:0.007466:0.012508:0.007466:0.007235:0.006042:0.005713:0.012604:0.018049:0.007235:0.010660:0.010660:0.014913:0.005330
to  30-35%.  The  median survival increases :@0.084242:0.919903:0.480476:0.919903:0.480476:0.904147:0.084242:0.904147:0.006523:0.012604:0.005330:0.003389:0.010660:0.010660:0.006388:0.010660:0.010672:0.014913:0.005330:0.005330:0.003391:0.008197:0.011738:0.012498:0.005330:0.003394:0.018049:0.012508:0.013181:0.003848:0.013143:0.011738:0.008736:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.008736:0.003848:0.011738:0.012450:0.005713:0.012508:0.013143:0.007466:0.012508:0.007466:0.005330
from eight to 10 months.:@0.084242:0.936228:0.309432:0.936228:0.309432:0.920472:0.084242:0.920472:0.006042:0.005711:0.012604:0.018049:0.005330:0.012508:0.003848:0.012950:0.011738:0.006523:0.005330:0.006523:0.012604:0.005330:0.010660:0.010660:0.005330:0.018049:0.012604:0.011738:0.006523:0.011738:0.007466:0.005330
Chemotherapy has a documented sur-:@0.523643:0.096149:0.914552:0.096149:0.914552:0.080393:0.523643:0.080393:0.015644:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.011488:0.011738:0.013143:0.007466:0.011488:0.013143:0.011488:0.013181:0.012604:0.012450:0.011699:0.018049:0.012508:0.011738:0.006523:0.012508:0.013181:0.011488:0.007466:0.011699:0.005792:0.006388
vival  benefit  in  patients  with  PS  of  0-1.  :@0.523643:0.112474:0.919875:0.112494:0.919875:0.096738:0.523643:0.096718:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330:0.004589:0.013123:0.012508:0.011738:0.012508:0.004686:0.004686:0.006523:0.005330:0.004562:0.003848:0.011738:0.005330:0.004574:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.004574:0.015990:0.003848:0.006523:0.011738:0.005330:0.004572:0.011392:0.009583:0.005330:0.004570:0.012604:0.006042:0.005330:0.004568:0.010660:0.006388:0.010660:0.005330:0.012433:0.399290
13:@0.902110:0.106875:0.914540:0.106875:0.914540:0.097689:0.902110:0.097689:0.006215:0.006215
Standard  chemotherapy  is the  platinum-:@0.523635:0.128818:0.914554:0.128818:0.914554:0.113062:0.523635:0.113062:0.009583:0.006523:0.013143:0.011738:0.013181:0.013143:0.005677:0.013181:0.005330:0.003125:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.003115:0.003848:0.007466:0.008467:0.006523:0.011738:0.012508:0.005330:0.003121:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.006388
based  doublet in which the agent used :@0.523635:0.145143:0.919867:0.145143:0.919867:0.129387:0.523635:0.129387:0.013123:0.013143:0.007466:0.012508:0.013181:0.005330:0.003706:0.013181:0.012604:0.011699:0.013123:0.003848:0.012508:0.006523:0.009025:0.003848:0.011738:0.009025:0.015990:0.011738:0.003848:0.012450:0.011738:0.009025:0.006523:0.011738:0.012508:0.009025:0.013143:0.012950:0.012508:0.011738:0.006523:0.009025:0.011699:0.007466:0.012508:0.013181:0.005330
with one of the platinums are vinorelbine, :@0.523635:0.161468:0.919911:0.161468:0.919911:0.145712:0.523635:0.145712:0.015990:0.003848:0.006523:0.011738:0.006388:0.012604:0.011738:0.012508:0.006379:0.012604:0.006042:0.006377:0.006523:0.011738:0.012508:0.006388:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.007466:0.006388:0.013143:0.005715:0.012508:0.006388:0.010660:0.003848:0.011738:0.012604:0.005715:0.012508:0.003848:0.013123:0.003848:0.011738:0.012508:0.005330:0.005330
gemcitabine, paclitaxel, docetaxel or :@0.523635:0.177793:0.919894:0.177793:0.919894:0.162037:0.523635:0.162037:0.012950:0.012508:0.018049:0.012450:0.003848:0.006523:0.013143:0.013123:0.003848:0.011738:0.012508:0.005330:0.017838:0.013123:0.013143:0.012450:0.003848:0.003848:0.006523:0.013143:0.009236:0.012508:0.003848:0.005330:0.017838:0.013181:0.012604:0.012450:0.012508:0.006523:0.013143:0.009236:0.012508:0.003848:0.017838:0.012604:0.005792:0.005330
pemetrexed.:@0.523635:0.194118:0.644818:0.194118:0.644818:0.178362:0.523635:0.178362:0.013123:0.012508:0.018049:0.012508:0.006523:0.005709:0.012508:0.009236:0.012508:0.013181:0.005330
Histology is  a predictive  factor. Pem-:@0.541819:0.210442:0.914533:0.210442:0.914533:0.194686:0.541819:0.194686:0.013143:0.003848:0.007466:0.006523:0.012604:0.003848:0.012604:0.012950:0.010314:0.012354:0.003848:0.007466:0.005330:0.007035:0.013143:0.012354:0.013123:0.005715:0.012508:0.013181:0.003848:0.012450:0.006523:0.003848:0.010660:0.012508:0.005330:0.007035:0.006042:0.013143:0.012450:0.006523:0.012604:0.004372:0.005330:0.012354:0.011392:0.012508:0.018049:0.006388
etrexed is more effective in patients with :@0.523635:0.226767:0.919894:0.226767:0.919894:0.211011:0.523635:0.211011:0.012508:0.006523:0.005707:0.012508:0.009236:0.012508:0.013181:0.007812:0.003848:0.007466:0.007812:0.018049:0.012604:0.005707:0.012508:0.007812:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.003848:0.010660:0.012508:0.007812:0.003848:0.011738:0.007812:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.007812:0.015990:0.003848:0.006523:0.011738:0.005330
adenocarcinoma, due to  higher  thymi-:@0.523635:0.243092:0.914558:0.243092:0.914558:0.227336:0.523635:0.227336:0.013143:0.013181:0.012508:0.011738:0.012604:0.012450:0.013143:0.005651:0.012450:0.003848:0.011738:0.012604:0.018049:0.013143:0.005330:0.011853:0.013181:0.011699:0.012508:0.011853:0.006523:0.012604:0.005330:0.006514:0.011738:0.003848:0.012950:0.011738:0.012508:0.005792:0.005330:0.006514:0.006523:0.011738:0.010314:0.018049:0.003848:0.006388
dylate synthase  levels in squamous cell :@0.523635:0.259417:0.919882:0.259417:0.919882:0.243661:0.523635:0.243661:0.013181:0.010314:0.003848:0.013143:0.006523:0.012508:0.011238:0.007466:0.010314:0.011738:0.006523:0.011738:0.013143:0.007466:0.012508:0.005330:0.005896:0.003848:0.012508:0.010660:0.012508:0.003848:0.007466:0.011238:0.003848:0.011738:0.011238:0.007466:0.013123:0.011699:0.013143:0.018049:0.012604:0.011699:0.007466:0.011238:0.012450:0.012508:0.003848:0.003848:0.005330
cancers.  There is no survival advantage; :@0.523635:0.275742:0.919876:0.275774:0.919876:0.260018:0.523635:0.259986:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.007466:0.005330:0.012428:0.006369:0.008197:0.011738:0.012508:0.005703:0.012508:0.006369:0.003848:0.007466:0.006369:0.011738:0.012604:0.006369:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.006385:0.013143:0.013181:0.010660:0.013143:0.011738:0.006523:0.013143:0.012950:0.012508:0.005330:0.161791
14:@0.604505:0.270155:0.616935:0.270155:0.616935:0.260969:0.604505:0.260969:0.006215:0.006215
only increased toxicity from administering :@0.523633:0.292099:0.919886:0.292099:0.919886:0.276343:0.523633:0.276343:0.012604:0.011738:0.003848:0.010314:0.006870:0.003848:0.011738:0.012450:0.005713:0.012508:0.013143:0.007466:0.012508:0.013181:0.006870:0.006523:0.012604:0.009236:0.003848:0.012450:0.003848:0.006523:0.010314:0.006870:0.006042:0.005711:0.012604:0.018049:0.006870:0.013143:0.013181:0.018049:0.003848:0.011738:0.003848:0.007466:0.006523:0.012508:0.005792:0.003848:0.011738:0.012950:0.005330
more than four to six cycles of chemother-:@0.523633:0.308423:0.914542:0.308423:0.914542:0.292667:0.523633:0.292667:0.018049:0.012604:0.005709:0.012508:0.005022:0.006523:0.011738:0.013143:0.011738:0.005022:0.006042:0.012604:0.011699:0.005782:0.005022:0.006523:0.012604:0.005013:0.007466:0.003848:0.009236:0.005022:0.012450:0.010314:0.012450:0.003848:0.012508:0.007466:0.005022:0.012604:0.006042:0.005022:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005759:0.006388
apy. This contrasts with biological and im-:@0.523633:0.324748:0.914506:0.324748:0.914506:0.308992:0.523633:0.308992:0.013143:0.013123:0.010314:0.005330:0.006215:0.008197:0.011738:0.003848:0.007466:0.006215:0.012450:0.012604:0.011738:0.006523:0.005792:0.013131:0.007466:0.006523:0.007466:0.006215:0.015990:0.003848:0.006523:0.011738:0.006215:0.013123:0.003848:0.012604:0.003848:0.012604:0.012950:0.003848:0.012450:0.013143:0.003848:0.006229:0.013143:0.011738:0.013181:0.006215:0.003848:0.018049:0.006388
mune therapy, which are given for as long :@0.523633:0.341073:0.919893:0.341073:0.919893:0.325317:0.523633:0.325317:0.018049:0.011699:0.011738:0.012508:0.004772:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.004780:0.015990:0.011738:0.003848:0.012450:0.011738:0.004776:0.013143:0.005715:0.012508:0.004776:0.012950:0.003848:0.010660:0.012508:0.011738:0.004780:0.006042:0.012604:0.005792:0.004770:0.013143:0.007466:0.004791:0.003848:0.012604:0.011738:0.012950:0.005330
as the patient is responding to treatment. :@0.523633:0.357398:0.919893:0.357398:0.919893:0.341642:0.523633:0.341642:0.013143:0.007466:0.006388:0.006523:0.011738:0.012508:0.006371:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.006379:0.003848:0.007466:0.006388:0.005711:0.012508:0.007466:0.013123:0.012604:0.011738:0.013181:0.003848:0.011738:0.012950:0.006377:0.006523:0.012604:0.006379:0.006523:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.005330
Therapy may be discontinued in the event :@0.523633:0.373722:0.919892:0.373722:0.919892:0.357967:0.523633:0.357967:0.008197:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.004643:0.018049:0.013143:0.010314:0.004657:0.013123:0.012508:0.004647:0.013181:0.003848:0.007466:0.012450:0.012604:0.011738:0.006523:0.003848:0.011738:0.011699:0.012508:0.013181:0.004657:0.003848:0.011738:0.004657:0.006523:0.011738:0.012508:0.004641:0.012508:0.010660:0.012508:0.011738:0.006523:0.005330
of unacceptable toxicity.:@0.523633:0.390047:0.759872:0.390047:0.759872:0.374291:0.523633:0.374291:0.012604:0.006042:0.005330:0.011699:0.011738:0.013143:0.012450:0.012450:0.012508:0.013123:0.006523:0.013143:0.013123:0.003848:0.012508:0.005330:0.006523:0.012604:0.009236:0.003848:0.012450:0.003848:0.006523:0.010314:0.005330
FIRST-LINE THERAPY  :@0.523636:0.423049:0.729722:0.423049:0.729722:0.405234:0.523636:0.405234:0.010263:0.005987:0.012401:0.011118:0.008980:0.008980:0.009407:0.005987:0.015822:0.011118:0.005987:0.008980:0.014539:0.011118:0.012401:0.015822:0.011973:0.013256:0.005965:0.005987
WITH BIOLOGICAL AGENTS:@0.523636:0.440850:0.794740:0.440850:0.794740:0.423034:0.523636:0.423034:0.019242:0.005987:0.008980:0.014539:0.005987:0.012401:0.005987:0.017960:0.009407:0.017960:0.017960:0.005987:0.016677:0.015822:0.009407:0.005987:0.015822:0.017960:0.011118:0.015822:0.008980:0.011118
Tyrosine kinase inhibitors (TKIs):@0.523636:0.458650:0.837501:0.458650:0.837501:0.440629:0.523636:0.440629:0.008980:0.012401:0.006842:0.013683:0.009407:0.005131:0.012828:0.013683:0.005987:0.012401:0.005131:0.012828:0.014111:0.009407:0.013683:0.005987:0.005131:0.012828:0.012828:0.005131:0.014111:0.005131:0.006414:0.013683:0.006842:0.009407:0.005987:0.008125:0.008980:0.013256:0.005987:0.009407:0.008125
Examples are erlotinib and gefitinib. Lung :@0.523636:0.476120:0.919891:0.476120:0.919891:0.460364:0.523636:0.460364:0.010314:0.009236:0.013143:0.018049:0.013123:0.003848:0.012508:0.007466:0.007102:0.013143:0.005715:0.012508:0.007087:0.012508:0.005792:0.003848:0.012604:0.006523:0.003848:0.011738:0.003848:0.013123:0.007091:0.013143:0.011738:0.013181:0.007091:0.012950:0.012508:0.004686:0.004686:0.006523:0.003848:0.011738:0.003848:0.013123:0.005330:0.007089:0.008890:0.011699:0.011738:0.012950:0.005330
cancers that are EGFR receptor mutation-:@0.523636:0.492444:0.914567:0.492444:0.914567:0.476688:0.523636:0.476688:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.007466:0.005253:0.006523:0.011738:0.013143:0.006523:0.005253:0.013143:0.005715:0.012508:0.005253:0.010314:0.016779:0.009333:0.011680:0.005253:0.005711:0.012508:0.012450:0.012508:0.013123:0.006523:0.012604:0.005792:0.005240:0.018049:0.011699:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.006388
positive will respond  to  these  agents.  :@0.523636:0.508769:0.919875:0.508776:0.919875:0.493020:0.523636:0.493013:0.013123:0.012604:0.007466:0.003848:0.006523:0.003848:0.010660:0.012508:0.012912:0.015990:0.003848:0.003848:0.003848:0.012912:0.005711:0.012508:0.007466:0.013123:0.012604:0.011738:0.013181:0.005330:0.007570:0.006523:0.012604:0.005330:0.007564:0.006523:0.011738:0.012508:0.007466:0.012508:0.005330:0.007572:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.005330:0.012414:-0.177119
15:@0.902110:0.503157:0.914540:0.503157:0.914540:0.493971:0.902110:0.493971:0.006215:0.006215
The  TKIs are taken  by mouth  daily. Their :@0.523635:0.525100:0.919892:0.525100:0.919892:0.509344:0.523635:0.509344:0.008197:0.011738:0.012508:0.005330:0.004143:0.008197:0.011372:0.004349:0.007466:0.009487:0.013143:0.005715:0.012508:0.009487:0.006523:0.013143:0.009660:0.012508:0.011738:0.005330:0.004147:0.013123:0.010314:0.009487:0.018049:0.012604:0.011699:0.006523:0.011738:0.005330:0.004139:0.013181:0.013143:0.003848:0.003848:0.010314:0.005330:0.009487:0.008197:0.011738:0.012508:0.003848:0.005792:0.005330
most frequent toxicities are rash and diar-:@0.523635:0.541425:0.914541:0.541425:0.914541:0.525669:0.523635:0.525669:0.018049:0.012604:0.007466:0.006523:0.006273:0.006042:0.005713:0.012508:0.013123:0.011699:0.012508:0.011738:0.006523:0.006273:0.006523:0.012604:0.009236:0.003848:0.012450:0.003848:0.006523:0.003848:0.012508:0.007466:0.006273:0.013143:0.005713:0.012508:0.006273:0.005792:0.013143:0.007466:0.011738:0.006273:0.013143:0.011738:0.013181:0.006273:0.013181:0.003848:0.013143:0.005792:0.006388
rhoea.  A study was undertaken  in East :@0.523635:0.557750:0.919881:0.557760:0.919881:0.542004:0.523635:0.541994:0.006342:0.011738:0.012604:0.012508:0.013143:0.005330:0.012425:0.009217:0.014239:0.009217:0.007466:0.006523:0.011699:0.013181:0.010314:0.009217:0.015990:0.013143:0.007466:0.009217:0.011699:0.011738:0.013181:0.012508:0.005792:0.006523:0.013143:0.009660:0.012508:0.011738:0.005330:0.003868:0.003848:0.011738:0.009217:0.010314:0.013143:0.007466:0.006523:-0.248375
16:@0.585290:0.552141:0.597720:0.552141:0.597720:0.542955:0.585290:0.542955:0.006215:0.006215
Asia where non-smokers  or  former  light :@0.523641:0.574085:0.919893:0.574085:0.919893:0.558329:0.523641:0.558329:0.014239:0.007466:0.003848:0.013143:0.011834:0.015990:0.011738:0.012508:0.005711:0.012508:0.011834:0.011738:0.012604:0.011738:0.006388:0.007466:0.018049:0.012604:0.009660:0.012508:0.005792:0.007466:0.005330:0.006494:0.012604:0.005792:0.005330:0.006492:0.006042:0.012604:0.006319:0.018049:0.012508:0.005792:0.005330:0.006494:0.003848:0.003848:0.012950:0.011738:0.006523:0.005330
smokers with advanced adenocarcino-:@0.523641:0.590409:0.914543:0.590409:0.914543:0.574653:0.523641:0.574653:0.007466:0.018049:0.012604:0.009660:0.012508:0.005792:0.007466:0.012604:0.015990:0.003848:0.006523:0.011738:0.012604:0.013143:0.013181:0.010660:0.013143:0.011738:0.012450:0.012508:0.013181:0.012604:0.013143:0.013181:0.012508:0.011738:0.012604:0.012450:0.013143:0.005650:0.012450:0.003848:0.011738:0.012604:0.006388
ma were randomised to either gefitinib or :@0.523641:0.606734:0.919902:0.606734:0.919902:0.590978:0.523641:0.590978:0.018049:0.013143:0.006196:0.015990:0.012508:0.005713:0.012508:0.006192:0.005792:0.013143:0.011738:0.013181:0.012604:0.018049:0.003848:0.007466:0.012508:0.013181:0.006202:0.006523:0.012604:0.006188:0.012508:0.003848:0.006523:0.011738:0.012508:0.005792:0.006190:0.012950:0.012508:0.004686:0.004686:0.006523:0.003848:0.011738:0.003848:0.013123:0.006192:0.012604:0.005792:0.005330
doublet chemotherapy as first-line thera-:@0.523641:0.623059:0.914551:0.623059:0.914551:0.607303:0.523641:0.607303:0.013181:0.012604:0.011699:0.013123:0.003848:0.012508:0.006523:0.008190:0.012450:0.011738:0.012508:0.018049:0.012594:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.008190:0.013143:0.007466:0.008199:0.004686:0.004686:0.005792:0.007466:0.006523:0.006388:0.003848:0.003848:0.011738:0.012508:0.008197:0.006523:0.011738:0.012508:0.005792:0.013127:0.006388
py. Among those patients whose tumours :@0.523641:0.639384:0.919893:0.639384:0.919893:0.623628:0.523641:0.623628:0.013123:0.010314:0.005330:0.006550:0.014239:0.018049:0.012604:0.011738:0.012950:0.006535:0.006523:0.011738:0.012604:0.007466:0.012508:0.006542:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.006550:0.015990:0.011738:0.012604:0.007466:0.012508:0.006546:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.007466:0.005330
harboured EGFR  mutations,  progression-:@0.523641:0.655708:0.914547:0.655708:0.914547:0.639953:0.523641:0.639953:0.011738:0.013143:0.005792:0.013123:0.012604:0.011699:0.005703:0.012508:0.013181:0.011430:0.010314:0.016779:0.009333:0.011680:0.005330:0.006090:0.018049:0.011699:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.005330:0.006088:0.013123:0.005715:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.006388
free  survival  was  significantly  longer  with :@0.523641:0.672033:0.919875:0.672033:0.919875:0.656277:0.523641:0.656277:0.006042:0.005711:0.012508:0.012508:0.005330:0.003795:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330:0.003810:0.015990:0.013143:0.007466:0.005330:0.003804:0.007466:0.003848:0.012950:0.011738:0.003848:0.004686:0.004686:0.012450:0.013143:0.011738:0.006523:0.003848:0.010314:0.005330:0.003797:0.003848:0.012604:0.011738:0.012950:0.012508:0.005792:0.005330:0.003785:0.015990:0.003848:0.006523:0.011738:0.005330
gefitinib.  Gefitinib  was  also  associated :@0.523641:0.688358:0.919875:0.688358:0.919875:0.672602:0.523641:0.672602:0.012950:0.012508:0.004686:0.004686:0.006523:0.003848:0.011738:0.003848:0.013123:0.005330:0.005330:0.009144:0.016779:0.012508:0.004686:0.004686:0.006523:0.003848:0.011738:0.003848:0.013123:0.005330:0.009159:0.015990:0.013143:0.007466:0.005330:0.009157:0.013143:0.003848:0.007466:0.012604:0.005330:0.009152:0.013143:0.007466:0.007466:0.012604:0.012450:0.003848:0.013143:0.006523:0.012508:0.013181:0.005330
with a better QoL. In the mutation-nega-:@0.523641:0.704683:0.914561:0.704683:0.914561:0.688927:0.523641:0.688927:0.015990:0.003848:0.006523:0.011738:0.007505:0.013143:0.007505:0.013123:0.012508:0.006523:0.006523:0.012508:0.005792:0.007495:0.016760:0.012604:0.008890:0.005330:0.007505:0.004349:0.011738:0.007505:0.006523:0.011738:0.012508:0.007505:0.018049:0.011699:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.006388:0.011738:0.012508:0.012950:0.013143:0.006388
tive group, gefitinib resulted in significantly :@0.523641:0.721008:0.919889:0.721008:0.919889:0.705252:0.523641:0.705252:0.006523:0.003848:0.010660:0.012508:0.005157:0.012950:0.005711:0.012604:0.011699:0.013123:0.005330:0.005153:0.012950:0.012508:0.004686:0.004686:0.006523:0.003848:0.011738:0.003848:0.013123:0.005159:0.005713:0.012508:0.007466:0.011699:0.003848:0.006523:0.012508:0.013181:0.005155:0.003848:0.011738:0.005155:0.007466:0.003848:0.012950:0.011738:0.003848:0.004686:0.004686:0.012450:0.013143:0.011738:0.006523:0.003848:0.010314:0.005330
shorter progression-free survival.:@0.523641:0.737332:0.818041:0.737332:0.818041:0.721576:0.523641:0.721576:0.007466:0.011738:0.012604:0.005792:0.006523:0.012508:0.005792:0.005330:0.013123:0.005696:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.006388:0.006042:0.005715:0.012508:0.012508:0.005330:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330
17:@0.818041:0.731749:0.830471:0.731749:0.830471:0.722563:0.818041:0.722563:0.006215:0.006215
When the tumour receptor status is un-:@0.541818:0.753696:0.914555:0.753696:0.914555:0.737940:0.541818:0.737940:0.018473:0.011738:0.012508:0.011738:0.007657:0.006523:0.011738:0.012508:0.007658:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.007651:0.005713:0.012508:0.012450:0.012508:0.013123:0.006523:0.012604:0.005792:0.007653:0.007466:0.006523:0.013143:0.006523:0.011699:0.007466:0.007668:0.003848:0.007466:0.007678:0.011699:0.011738:0.006388
known,  chemotherapy  remains  first-line :@0.523634:0.770021:0.919875:0.770021:0.919875:0.754265:0.523634:0.754265:0.009660:0.011738:0.012604:0.015990:0.011738:0.005330:0.005330:0.009136:0.012450:0.011738:0.012508:0.018049:0.012594:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.009146:0.005711:0.012508:0.018049:0.013143:0.003848:0.011738:0.007466:0.005330:0.009154:0.004686:0.004686:0.005792:0.007466:0.006523:0.006388:0.003848:0.003848:0.011738:0.012508:0.005330
therapy.:@0.523634:0.786345:0.602104:0.786345:0.602104:0.770589:0.523634:0.770589:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
Vascular endothelial growth factor :@0.523636:0.819331:0.887104:0.819331:0.887104:0.801310:0.523636:0.801310:0.014966:0.014111:0.009407:0.013683:0.012828:0.005131:0.014111:0.006842:0.005987:0.013683:0.012828:0.014111:0.013683:0.006414:0.012828:0.013683:0.005131:0.005131:0.014111:0.005131:0.005987:0.014111:0.006842:0.013683:0.017104:0.006414:0.012828:0.005987:0.005987:0.014111:0.013683:0.006414:0.013683:0.006842:0.005987
receptor (VEGFR):@0.523636:0.837132:0.701521:0.837132:0.701521:0.819111:0.523636:0.819111:0.006842:0.013683:0.013683:0.013683:0.014111:0.006414:0.013683:0.006842:0.005987:0.008125:0.014966:0.011118:0.017960:0.010263:0.012401:0.008125
Bevacizumab is an antibody to the ligand :@0.523636:0.854604:0.919887:0.854604:0.919887:0.838848:0.523636:0.838848:0.011045:0.012508:0.010660:0.013143:0.012450:0.003848:0.008178:0.011699:0.018049:0.013143:0.013123:0.005638:0.003848:0.007466:0.005638:0.013143:0.011738:0.005638:0.013143:0.011738:0.006523:0.003848:0.013123:0.012604:0.013181:0.010314:0.005638:0.006523:0.012604:0.005626:0.006523:0.011738:0.012508:0.005623:0.003848:0.003848:0.012950:0.013143:0.011738:0.013181:0.005330
of the VEGFR. It is not used in patients with :@0.523636:0.870928:0.919895:0.870928:0.919895:0.855173:0.523636:0.855173:0.012604:0.006042:0.005340:0.006523:0.011738:0.012508:0.005336:0.013508:0.010314:0.016779:0.009333:0.011680:0.005330:0.005349:0.004349:0.006523:0.005349:0.003848:0.007466:0.005349:0.011738:0.012604:0.006523:0.005334:0.011699:0.007466:0.012508:0.013181:0.005349:0.003848:0.011738:0.005349:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005349:0.015990:0.003848:0.006523:0.011738:0.005330
squamous carcinoma because of con-:@0.523636:0.887253:0.914565:0.887253:0.914565:0.871497:0.523636:0.871497:0.007466:0.013123:0.011699:0.013143:0.018049:0.012604:0.011699:0.007466:0.011969:0.012450:0.013143:0.005657:0.012450:0.003848:0.011738:0.012604:0.018049:0.013143:0.011969:0.013123:0.012508:0.012450:0.013143:0.011699:0.007466:0.012508:0.011969:0.012604:0.006042:0.011969:0.012450:0.012604:0.011738:0.006388
cerns about increased haemorrhage.:@0.523636:0.903578:0.875447:0.903578:0.875447:0.887822:0.523636:0.887822:0.012450:0.012508:0.006188:0.011738:0.007466:0.005330:0.013143:0.013123:0.012604:0.011699:0.006523:0.005330:0.003848:0.011738:0.012450:0.005705:0.012508:0.013143:0.007466:0.012508:0.013181:0.005330:0.011738:0.013143:0.012508:0.018049:0.012604:0.005792:0.006331:0.011738:0.013143:0.012950:0.012508:0.005330
A randomised study evaluated the ad-:@0.541820:0.919903:0.914559:0.919903:0.914559:0.904147:0.541820:0.904147:0.014239:0.007416:0.005792:0.013143:0.011738:0.013181:0.012604:0.018049:0.003848:0.007466:0.012508:0.013181:0.007428:0.007466:0.006523:0.011699:0.013181:0.010314:0.007428:0.012508:0.010660:0.013143:0.003848:0.011699:0.013143:0.006523:0.012508:0.013181:0.007428:0.006523:0.011738:0.012508:0.007414:0.013143:0.013181:0.006388
dition of bevacizumab to carboplatin :@0.523636:0.936228:0.919856:0.936228:0.919856:0.920472:0.523636:0.920472:0.013181:0.003848:0.006523:0.003848:0.012604:0.011738:0.015529:0.012604:0.006042:0.015529:0.013123:0.012508:0.010660:0.013143:0.012450:0.003848:0.008178:0.011699:0.018049:0.013143:0.013123:0.015529:0.006523:0.012604:0.015529:0.012450:0.013143:0.005792:0.013123:0.012604:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.005330